雷贝拉唑与奥美拉唑三联疗法治疗幽门螺杆菌阳性消化性溃疡的疗效比较

目的比较雷贝拉唑与奥美拉唑三联疗法治疗幽门螺杆菌（HP）阳性消化性溃疡的疗效。方法将经胃镜检查确认为Hp阳性的活动性消化性溃疡患者74例,随机方法分为两组。治疗组37例,口服雷贝拉唑10mg,阿莫西林1000mg及克拉霉素500mg,2次／d,治疗1周后继续单独口服雷贝拉唑10mg,2次／d;对照组37例,口服奥美拉唑20mg,阿莫西林1000mg及克拉霉素500mg,2次／d,治疗1周后继续单独口服奥美拉唑20mg,2次／d。两组十二指肠球部溃疡疗程为4周,胃溃疡为6周。用药结束4周后复查胃镜并检测Hp。结果治疗组和对照组用药1d的临床症状缓解率分别为81％和57％,差异有统计学意义（P〈0．05）;7d后症状缓解率分别为97％和92％,差异无统计学意义（P〉0．05）。溃疡愈合率分别为92％和76％,差异有统计学意义（P〈0．05）;治疗溃疡总有效率分别为97％和92％,差异无统计学意义（P〉0．05）。Hp根除率分别为89％和84％,差异无统计学意义（P〉0．05）。结论两组均能有效缓解消化性溃疡的临床症状和促进溃疡愈合及根除Hp,但雷贝拉唑三联疗法在改善临床症状及促进溃疡愈合方面优于奥美拉唑三联疗法。     

雷贝拉唑、阿莫西林二联疗法治疗幽门螺杆菌相关性溃疡

目的 评估雷贝拉唑、阿莫西林二联疗法治疗幽门螺杆菌（Helicobacter pylori，Hp）相关性溃疡的疗效。方法 120例经胃镜检查确诊为胃和十二指肠溃疡并经快速尿素酶法和病理学特染法测定为Hp阳性的病人随机分为两组：雷贝拉唑组和奥美拉唑组。两组分别予以二联疗法；雷贝拉唑10mg或奥美拉唑20mg，1次／d；阿莫西林0．5g，3次／d；连续2周。疗程结束后4周复查胃镜并检测Hp，并记录用药后病人症状的改变程度。结果 雷贝拉唑组溃疡愈合率为94．3％，奥美拉唑组72．0％，两组比较有显著的差异性（P〈0．05）。雷贝拉唑组第1、3d症状缓解率分别为81．4％、94．3％。奥美拉唑组为38．0％、64．0％，两组有显著性差异（P〈0.05）。雷贝拉唑组Hp清除率为91．4％，奥美拉唑组为88．0％，两组无统计学差异（P〉0．05）。结论 雷贝拉唑、阿莫西林二联疗法能提高溃疡愈合率及迅速缓解症状，并能有效根除Hp。与奥美拉唑组相比较，雷贝拉唑组在溃疡愈合率及症状缓解率方面更显优势。     

潘托拉唑治疗消化性溃疡临床疗效观察

目的：研究潘托拉唑治疗消化性溃疡的疗效及安全性。方法：将经胃镜证实的消化性溃疡患者随机分成潘托拉唑组（治疗组,简称潘组）和奥美拉唑组（对照组,简称奥组）,其中潘组60例,应用潘托拉唑40mg,1次／d;奥组58例;应用败类美拉唑20mg,1次／d。十二指肠溃疡患者疗程4周,胃溃疡6周。停药后均复查胃镜观察溃疡愈合情况。治疗期间每周随访1次。并记录症状改善情况及不良反应。结果：十二指肠溃疡的愈合率两组分别为91．7％和94．7％,胃溃疡的愈合率两组分别为91．7％反应。结果十二指肠溃疡的愈合率两组分别为91．7％和94．7％,胃溃疡的愈合率两组分别为91．7％和90．0％,P值均＞0．05。各项症状的改善情况两组相仿（P＞0．05）。治疗期间,两组均有良好的耐受性。结论潘托拉唑对消化性溃疡有较高的治愈率和症状改善率。疗效与奥美拉唑相当,其不良反应很少,患者耐受性好,是一种有应用前景的质子泵抑制剂。     

奥美拉唑三联合用雷尼替丁治疗消化性溃疡36例

目的验证奥美拉唑三联合用雷尼替丁治疗消化性溃疡的疗效方法选经内镜确诊为活动期消化性溃疡患者71例，随机分为治疗组（n=36）和对照组（n=35）．治疗组服用奥美拉唑（阿斯特拉公司生产）20mg，每天睡前一次，服4wk后改用雷尼替丁150mg，每天睡前一次，服1wk，羟氨苄青霉素500mg，3次／d，替硝唑1.0，2次／d，服2wk；对照组服用奥美拉唑（阿斯特拉公司生产）20mg，每天早晨一次，服4wk，羟氨苄青霉素500mg，3次／d，替硝唑1．0，2次／d，服2wk．治疗后记录腹痛消失时间及副作用，疗程结束后4wk做内镜，判断溃疡愈合情况，并对患者进行1a的追踪．结果消化性溃疡一疗程的愈合率和有效率，治疗组分别为94．4％和97．2％，对照组分别为91．4％和97．1％，两组间无显著性差异（P＞0．05），而＆期溃疡愈合率治疗组（61．1％）明显高于对照组（37．1％，P＜0．05）；疼痛消失率分别为97％和96．9％，两组间无显著性差异（P＞0．05），而3d内疼痛消失率治疗组为78．8％．对照组为53．1％都有显著性差异（P＜0．05）；年溃疡复发率分别为8．8％和12．5％，两组差异无显著性（P＞0．05）．两组治疗过程中未发现有副作用．结论奥美拉唑合用雷尼替丁并采用睡前服药能提高其治疗消化性溃疡的近、远期疗效．     

埃索美拉唑与奥美拉唑治疗胃溃疡的临床分析

目的对比埃索美拉唑与奥美拉唑治疗胃溃疡的疗效。方法将经胃镜证实的胃溃疡病人随机分为埃索美拉唑组（治疗组60例）与奥美拉唑组（对照组58例）。治疗组应用埃索美拉唑40mg,对照组用奥美拉唑20Ing均睡前服,治疗3周、6周后均复查胃镜,观察溃疡愈合情况。结果治疗3周后治疗组和对照组病人胃镜下胃溃疡的愈合率、显效率、有效率分别是36．7％和17．2％、75．0％和43．1％、95．0％和72．4％,治疗组疗效明显高于对照组,两组差异具有统计学意义（P〈0．05）;治疗6周后治疗组和对照组病人胃镜下胃溃疡的愈合率、显效率、有效率分别是40．0％和37．9％、86．7％和81．0％、98．3％和96．6％,两组比较差异无统计学意义（P〉0．05）。结论埃索美拉唑与奥美拉唑治疗胃溃疡的愈合率、显效率、有效率相当,但埃索美拉唑起效快,治疗时间短,不良反应少,值得在临床上广泛应用。     

雷贝拉唑治疗幽门螺杆菌阳性十二指肠溃疡45例疗效观察

将87例幽门螺旋杆菌（HP）阳性十二指肠溃疡患者随机分为治疗组（雷贝拉唑组）45例和对照组（奥美拉唑组）42例，并同时加用阿莫西林和甲硝唑治疗，4周为一疗程。停药后4周行胃镜及HP检测。结果治疗组疼痛消失时间较对照组缩短，P〈0．05；两组1周末、2周末的症状消失率、溃疡愈合率、HP根除率治疗组均高于对照组，但均无显著差异。提示雷贝拉唑治疗HP阳性十二指肠溃疡有较高的溃疡愈合率、HP根除率．且止痛效应快，不良反应发生率较低．     

潘托拉唑三联疗法与奥美拉唑三联疗法治疗幽门螺杆菌相关性消化性溃疡

目的：研究潘托拉唑治疗消化性溃疡及根除幽门螺杆菌（HP）的疗效和安全性。方法：将经过胃镜和病理学检查证实了的消化性溃疡患者随机分成潘托拉唑组（治疗组）和奥美拉唑组（对照组）。其中治疗组60例,应用潘托拉唑、羟氨苄青霉素和甲硝唑治疗;对照组57例,应用奥美 拉唑、羟氨苄青霉素和甲硝唑治疗。停药后均复查胃镜观察溃疡愈合情况以及HP根除情况。结果：两组胃溃疡的愈合率分别为92．3％和95．4％,HP根除率分别为92．3％和90．9％;十二指肠溃疡的愈合率分别为97．1％和94．3％,HP根除率分别为91．2％和94．3％,两组比较差异无显著性（P＞0．01）,各项症状的改善情况两组相似（P＞0．1）。治疗期间两组均有良好的耐受性。结论：潘托拉唑对消化性溃疡有很高的治愈率,以它为主的三联疗法可达到很高的HP根除率,对消化性溃疡的疗效与奥美拉唑相当,不良反应极少,患者耐受性,依从性好,是一种有广泛应用前景的新型质子泵抑制剂。     

雷贝拉唑三联疗法治疗幽门螺杆菌阳性十二指肠溃疡

目的观察雷贝拉唑三联短程疗法治疗幽门螺杆菌(H.pylori)阳性十二指肠溃疡的疗效.方法100例经胃镜检查确诊为十二指肠溃疡并经快速尿素酶实验和病理学检查确定为H.pylori阳性的患者随机分为两组雷贝拉唑组和奥美拉唑组.两组先予以三联疗法雷贝拉唑10mg或奥美拉唑20mg、阿莫西林1g及克拉霉素500mg,每日2次,连续7天,然后给予雷贝拉唑10mg或奥美拉唑20mg,每天1次,连续7天,疗程结束后4周复查胃镜并检测H.pylori,并记录用药后患者症状的改变程度.结果93例完成治疗方案.其中雷贝拉唑组2周溃疡愈合率为93.6%,奥美拉唑组为73.9%,雷贝拉唑组明显高于奥美拉唑组,两组有显著性差异(P＜0.05),雷贝拉唑组第1、3天症状缓解率分别为68.1%、91.4%,奥美拉唑组为39.1%、65.2%,两组比较差异有显著性(P＜0.05);雷贝拉唑H.pylori根除率为91.5%,奥美拉唑组为86.9%,两组间无显著性差异(P＞0.05).结论雷贝拉唑、克拉霉素和阿莫西林三联短程疗法能有效根除H.pylori及提高溃疡愈合率,并能迅速缓解症状,与奥美拉唑三联疗法相比较,在H.pylori根除率上无显著性差异,而在2周溃疡愈合率及症状缓解率方面,雷贝拉唑却明显优于奥美拉唑.     

疣状胃炎氩离子凝固术后质子泵抑制剂疗效的比较

背景：质子泵抑制剂（PPI）埃索美拉唑和奥美拉唑广泛应用于消化性溃疡和反流性食管炎的治疗中，但目前内镜下治疗术后的应用研究较少。目的：比较埃索美拉唑与奥美拉唑对疣状胃炎氩离子凝固术（APC）后腹痛缓解和溃疡愈合的疗效。方法：86例疣状胃炎APC后随机分为两组：A组46例，治疗后次日起予埃索美拉唑20mg／d口服．疗程4周；B组40例，治疗后次日起予奥美拉唑20mg／d口服，疗程4周。观察治疗前后两组患者的腹痛缓解情况和溃疡愈合情况。溃疡愈合情况通过胃镜检查来评估。结果：A组患者服药后第ld腹痛缓解率为84．8％，高于B组的55．0％（心0．001）。A组患者第7d腹痛缓解率为100，0％，高于B组的80．0％（P〈0．01）。两组间疼痛消失平均天数比较，A组显著少于B组（P〈0．001）。A组溃疡愈合率（95．7％）高于B组（92．5％），但差异无显著性（P〉0．05）。结论：埃索美拉唑和奥美拉唑在疣状胃炎APC后溃疡的愈合方面具有相同疗效，但在腹痛缓解方面埃索美拉唑优于奥美拉唑。     

枸橼酸铋雷尼替丁治疗消化性溃疡46例

目的总结国产枸橼酸铋雷尼替丁（舒威）治疗消化性溃疡的疗效。方法随机将86例消化性溃疡患者分为两组，治疗组45例，用舒威0．4g，po，bid；对照组41例，用奥美拉唑20mg，po，qd，疗程均为4周。结果治疗组和对照组的溃疡愈合率分别为88．9％和90．2％，有效率为93．3％和95．1％，差异均无显著性（P〉0．05）。消化道症状消失率分别为82．2％和92．7％，4周内溃疡性疼痛消失率分别为73．8％和86．8％，3天内疼痛消失率分别为31．0％和50％，1周内疼痛消失率分别为21．4％和26．3％，差异均有显著性（P〈0．05）。结论舒威治疗消化性溃疡效果较好。     

Comparison of the efficacy of rabeprazole 10 mg and omeprazole 20 mg for the healing rapidity of peptic ulcer diseases

AIM: Rabeprazole has been known to inhibit H(+)/K(+)-ATPase more rapidly than omeprazole, the prototype proton pump inhibitor (PPI). The aim of this study was to demonstrate equivalence between low-dose rabeprazole 10 mg and omeprazole 20 mg for the healing rapidity of active peptic ulcer and for improvement of symptoms. Also, the effect of CYP2C19 genotypes on ulcer healing rapidity was investigated. METHODS: A total of 112 patients with active peptic ulcer were randomized to receive either rabeprazole 10 mg q.d. or omeprazole 20 mg q.d. for 6 weeks. The remaining ratios (%) and complete healing of the ulcer were determined by endoscopy at 1 week and 6 weeks of treatment. The severity of ulcer pain was also investigated during treatment. CYP2C19 genotype was determined by the polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) method. RESULTS: The remaining ratio of peptic ulcers after 1 week and the complete healing rate after 6 weeks in the rabeprazole versus omeprazole group were 45.5% versus 50.3% (P = 0.475) and 80.6% versus 87.0% (P = 0.423), respectively. CYP2C19 genotypes had no effect on the remaining ratio of peptic ulcers after 1 week and the healing rate of peptic ulcers after 6 weeks in both groups. The proportions of patients with symptom improvement or resolution were comparable between the two groups. CONCLUSION: Low-dose rabeprazole 10 mg has a similar efficacy for the healing rapidity of active peptic ulcer disease and symptom improvement compared with standard-dose omeprazole 20 mg.     

Eradication therapy with rabeprazole versus omeprazole in the treatment of active duodenal ulcer

BACKGROUND: Rabeprazole has been demonstrated to be a potent antisecretory agent and has been shown to be clinically effective in the treatment of acid-related diseases. AIMS: It was to determine the efficacy of rabeprazole at 20 and 40 mg in addition to amoxicillin and clarithromycin in the treatment of active Helicobacter pylori-positive duodenal ulcers compared with omeprazole 40 mg. PATIENTS AND METHODS: One hundred and twenty-seven patients were randomised into three treatment groups: 40 patients were treated with rabeprazole 40 mg daily, 42 patients with rabeprazole 20 mg daily and 45 patients with omeprazole 40 mg daily for 10 days. All patients received amoxicillin 1 g twice a day and clarithromycin 500 mg twice a day for 5 days. All patients were re-assessed at least 4 weeks after the end of the treatment. RESULTS: According to the intention-to-treat (ITT) protocol, ulcer healing was observed in 90% of patients in the rabeprazole 40 group, in 85.7% in the rabeprazole 20 group and in 93.3% in the omeprazole 40 group. We observed H. pylori eradication in 90% ITT in the rabeprazole 40 group, in 80.9% ITT in the rabeprazole 20 group and in 88.8% ITT in the omeprazole 40 group. Statistical analysis did not show significant differences among the three groups. CONCLUSIONS: A 10-day rabeprazole 20 mg regimen represents an efficacious and safe regimen for H. pylori eradication and ulcer healing.     

The benefit/risk profile of rabeprazole, a new proton-pump inhibitor

Acid-related diseases such as gastro-oesophageal reflux disease (GORD) and peptic ulcer are a common cause of morbidity and if inadequately treated can lead to serious complications. The proton-pump inhibitor rabeprazole has been extensively evaluated in well-controlled trials in North America and Europe for the acute treatment of erosive or ulcerative GORD and gastric and duodenal ulcers and for the long-term maintenance of GORD healing. The results show that rabeprazole has a favourable benefit/risk profile for each indication. Rabeprazole 10 and 20 mg given once daily in the morning was highly effective in producing and maintaining healing, providing symptom relief, and improving overall well-being. Healing rates for rabeprazole were equivalent to omeprazole in all indications, and superior (GORD healing and duodenal ulcer healing) or equivalent (gastric ulcer healing) to the histamine 2-receptor antagonist ranitidine. Symptom relief provided by rabeprazole was equivalent or superior to comparator drugs. Rabeprazole was well tolerated in both short- and long-term studies. The incidence of treatment-emergent signs and symptoms related to rabeprazole was low, and these were generally mild or moderate in severity. The overall rate of discontinuations due to adverse events was approximately 3%. There were no deaths related to rabeprazole therapy. These findings indicate a favourable benefit/risk profile for each intended use.     

雷贝拉唑与奥美拉唑三联疗法根除幽门螺杆菌多中心、随机、双盲、平行对照研究

背景:新一代质子泵抑制剂雷贝拉唑具有较高的解离常数（pKa）,在抑酸方面起效更快,作用更持久稳定。目的:通过与奥美拉唑三联疗法比较,观察雷贝拉唑三联疗法根除幽门螺杆菌（H.pylori）和治疗十二指肠溃疡的疗效。方法:采用多中心、随机、双盲、平行对照研究方法,于2002年1～7月在5家医院进行。109例经胃镜检查确诊为十二指肠溃疡活动期并经快速尿素酶试验和病理学检查确定为H.pylori阳性的患者分为两组:雷贝拉唑（商品名:波利特）试验组（RAC组,53例）和奥美拉唑（商品名:洛赛克）对照组（OAC组,56例）。两组均先给予三联治疗:雷贝拉唑10mg或奥美拉唑20mg+阿莫西林1g+克拉霉素500mg,每日2次,连续7天,然后单独给予雷贝拉唑10mg,每日1次或奥美拉唑20g,每日1次,连续7天,并于用药结束后第28天复查胃镜并检测H.pylori。于用药后第1、2、3、6和42天对患者的上腹痛、反酸以及上腹烧灼感等症状进行评估。结果:101例患者完成全部治疗方案,8例失访。H.pylori根除率:病理学检查结果显示RAC组的H.pylori根除率为86.0％,OAC组为76.5％,两组间差异无显著性（P>0.05）。溃疡愈合率:PAC组的溃疡愈合率为92.0％,OAC组为76.5％,OAC组高于OAC组,两组间差异有显著性（P<0.05）。症状改善情况:两组从用药第1天起均能有效改善     

Evaluation of efficacy,safety and tolerability rabeprazole in treatment of acid-peptic diseases

BACKGROUND: Rabeprazole, a substituted benzimidazole, represents a new generation of proton pump inhibitors that has recently been approved by the FDA and European Union for treatment of acid-related diseases. OBJECTIVES: To assess the efficacy and tolerability of rabeprazole 20 mg in actual conditions of use in everyday clinical practice on subjects with diagnosis of erosive gastroesophageal reflux disease and/or gastric and/or duodenal ulcer. PATIENTS/METHODS: A total of 171 outpatients (55% men, 45% women) with a mean age of 42.5 years were enrolled in this trial. The majority of subjects (81.0%) were Caucasians. Patients with endoscopically confirmed erosive/ulcerative gastroesophageal reflux disease (Savary-Miller classification), duodenal ulcer and/or benign gastric ulcer were eligible to receive rabeprazole 20 mg once daily for 4 to 8 weeks, depending on the diagnosis and at investigators' discretion. Patients were requested to record their symptoms in a diary card in a daily basis. RESULTS: One hundred and sixty two patients completed the study in accordance with the protocol. Reflux esophagitis was diagnosed in 78 (48.1%) patients, duodenal ulcer in 39 (24.1%) and gastric ulcer in 24 (14.8%). Eleven (6.8%) patients presented reflux esophagitis associated with duodenal ulcer and 7 (4.3%) associated with gastric ulcer. Finally, 3 (1.9%) presented both gastric and duodenal ulcer. Fifty-three percentage of patients were free of symptoms on the first day of treatment and 89.5% after a week. The healing rate was 84.4% for patients with reflux esophagitis, 90.6% for duodenal ulcer and 90.9% for gastric ulcer. The adverse effects were minimal and transitory. CONCLUSIONS: Rabeprazole is highly effective and well tolerated in acute healing of reflux esophagitis and peptic ulcers. In addition, it provides fast symptoms relief.     

雷贝拉唑与奥美拉唑对十二指肠溃疡患者症状的短期疗效

目的　评价短期应用雷贝拉唑和奥美拉唑对十二指肠溃疡 (DU)患者症状的治疗作用及其安全性。方法　多中心、随机、双盲、平行对照研究。将活动期DU患者随机分为雷贝拉唑 (1 0mg/d)治疗组和奥美拉唑 (2 0mg/d)对照组。 2组均服药 7d。记录治疗前和用药期间的腹痛、反酸、腹胀和嗳气症状的变化及有无不良反应出现。结果　治疗组和对照组分别完成了 1 0 8例和 1 0 3例患者的观察。治疗组的腹痛平均消失天数为 (3 1± 1 7)d ,与对照组 (3 2± 1 8)d相同。治疗组和对照组服药期间每天的腹痛消失率无明显差异。用药第 1天时治疗组的腹痛缓解率为 56 % ,明显高于对照组的 33 % (P <0 0 5) ,其余各天内 2组间无差异。治疗组患者第 7天的反酸消失率为 1 0 0 % ,明显高于对照组的 83 % (P <0 0 5)。 2组患者的每天腹胀和嗳气的消失率差异均无显著性。 2组均无不良反应发生。结论　雷贝拉唑及奥美拉唑均对DU患者的症状具有良好的治疗作用 ,而雷贝拉唑在服药第 1天对腹痛及第 7天对反酸的缓解作用更为明显。雷贝拉唑短期应用具有良好的安全性     

Rabeprazole is superior to ranitidine in the management of active duodenal ulcer disease: results of a double-blind, randomized North American study

OBJECTIVE: The primary purpose of this study was to compare the efficacy and tolerability of rabeprazole versus ranitidine in the treatment of patients with active duodenal ulcer disease. METHODS: This multicenter, double-blind, randomized, parallel-group study enrolled 376 patients. Patients were randomly assigned to receive rabeprazole 20 mg administered once daily in the morning (q.a.m.) with matching ranitidine placebo twice daily (b.i.d.) (n = 188), or ranitidine 150 mg b.i.d. with matching rabeprazole placebo q.a.m. (n = 188). Three visits were scheduled: wk 0 (baseline; days -3 to -1), wk 2 (day 15+/-3 days), and wk 4 (day 29+/-3 days). The primary efficacy response variable was defined as complete regeneration of the mucosa at the site of all ulcers identified during the study. Secondary efficacy variables included patients' ratings of frequency and severity of ulcer pain, frequency of antacid use, and improvement of overall physical well-being. Tolerability was evaluated with analyses of adverse events, laboratory evaluations, fasting serum gastrin levels, vital signs, body weight, and electrocardiograms. RESULTS: Up to 4 wk of treatment with rabeprazole 20 mg q.a.m. produced significantly greater healing rates, compared to treatment with ranitidine 150 mg b.i.d. (83% vs 73%; p = 0.017). Significant differences between treatment groups were also observed for secondary efficacy indices. At wk 2, rabeprazole was more likely than ranitidine to produce complete resolution of duodenal ulcer pain (39% vs 25%; p = 0.006), improvement in duodenal ulcer nighttime pain severity (76% vs 65%; p = 0.044), and improvement in overall well-being (55% vs 41%; p = 0.009). At wk 4, the proportion of patients with normalization of overall well-being was significantly higher in the rabeprazole group than in the ranitidine group (45% vs 29%; p = 0.003). Rabeprazole was safe and well tolerated in this study. CONCLUSIONS: In patients with active duodenal ulcer disease, rabeprazole 20 mg q.a.m. is superior to ranitidine 150 mg b.i.d. in healing, resolving ulcer pain frequency, improving nighttime pain severity, and improving overall well-being. Rabeprazole is an effective and well-tolerated alternative treatment for patients with active duodenal ulcer disease.     

Rabeprazole in Treatment of Acid Peptic Diseases (Results of Three Placebo-Controlled Dose-Response Clinical Trials in Duodenal Ulcer, Gastric Ulcer, and Gastroesophageal Reflux Disease (GERD))

Rabeprazole, a new proton pump inhibitor, wasstudied in patients with acid-pepticrelated diseases(duodenal ulcer, gastric ulcer, GERD) in threeplacebo-controlled, double-blind, randomized clinicaltrials. Men and women over the age of 18 were enrolledif the presence of an active duodenal or gastric ulceror erosive or ulcerative esophagitis was confirmed onupper gastrointestinal endoscopy. Patients were randomly allocated to either placebo orrabeprazole 20 mg or 40 mg in the duodenal and gastriculcer protocols or to placebo or rabeprazole 10 mg, 20mg, or 40 mg in the GERD protocol. All doses ofrabeprazole in all three studies were statisticallysignificantly superior to placebo in healingacid-related lesions. There were no treatmentdifferences between the rabeprazole doses in healingactive peptic lesions. The incidence of positive [¹³C]ureabreath test for H. pylori was 53% in patients withduodenal or gastric ulcers. H. pylori status was noteffected by treatment with rabeprazole.     

REVIEW: Efficacy of Rabeprazole Once Daily for Acid-Related Disorders

Proton-pump inhibitors (PPIs) have revolutionized the treatment of gastroesophageal reflux disease (GERD) and peptic ulcer. To evaluate the efficacy of the new PPI rabeprazole, 12 controlled clinical trials were conducted worldwide—three for each indication (erosive or ulcerative GERD healing, long-term GERD healing maintenance, duodenal ulcer healing, and gastric ulcer healing). Rabeprazole was compared to placebo, the H₂-receptor antagonist ranitidine, and the PPI omeprazole. Treatment duration ranged from 4 weeks for duodenal ulcer to 6 weeks for gastric ulcer, 8 weeks for GERD healing, and 1 year for maintenance of GERD healing. Rabeprazole was as effective as omeprazole for each indication and significantly more effective than ranitidine for healing of GERD (87% vs 66%) and duodenal ulcer (83% vs 73%). Rabeprazole was also superior to ranitidine in providing symptom relief, particularly in GERD.